Efficacy and safety of retreatment with Elbasvir/Grazoprevir associated to Sofosbuvir plus /- Ribavirin in HCV infected patients with a previous failure to therapy with direct-acting antiviral drugs

被引：0
|
作者：
Alric, Laurent [1 ]
Leroy, Vincent [2 ]
Cotte, Laurent [3 ]
Anne, Minello [4 ]
Remy, Andre Jean [5 ]
Rouanet, Isabelle [6 ]
Godart, Marion [1 ]
Hezode, Christophe [7 ]
Abravanel, Florence [8 ]
Ollivier-Hourmand, Isabelle [9 ]
机构：
[1] CHU Purpan, Internal Med Digest Dept, Toulouse, France
[2] CHU, Digest Dept, Grenoble, France
[3] Hop Lyon, Digest Dept, Lyon, France
[4] CHU, Digest Dept, Dijon, France
[5] Hop Perpignan, Digest Dept, Perpignan, France
[6] CHU, Digest Dept, Nimes, France
[7] CHU Henri Mondor, Digest Dept, Creteil, France
[8] CHU Purpan, Virol, Toulouse, France
[9] CHU, Digest Dept, Caen, France
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1544
引用
收藏
页码：824A / 825A
页数：2
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRAL THERAPIES FOR HEPATITIS C VIRUS INFECTION IN PATIENTS RECEIVING OPIOID SUBSTITUTION THERAPY
    Grebely, Jason
    Feld, Jordan J.
    Wyles, David
    Sulkowski, Mark S.
    Ni, Liyun
    Llewellyn, Joe
    Mir, Heshaam
    Sajed, Nika
    Stamm, Luisa M.
    Hyland, Rob
    McNally, John
    Brainard, Diana
    Jacobson, Ira
    Zeuzem, Stefan
    Bourliere, Marc
    Foster, Graham
    Afdhal, Nezam
    Dore, Gregory J.
    DRUG AND ALCOHOL REVIEW, 2017, 36 : 34 - 35
  • [32] Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Takeuchi, Yasue
    Akuta, Norio
    Sezaki, Hitomi
    Suzuki, Fumitaka
    Fujiyama, Shunichiro
    Kawamura, Yusuke
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Saitoh, Satoshi
    Suzuki, Yoshiyuki
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    HEPATOLOGY RESEARCH, 2019, 49 (03) : 256 - 263
  • [33] SAFETY AND EFFICACY OF SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRAL AGENTS IN KIDNEY TRANSPLANT RECIPIENTS WITH HCV: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Wang, Xianding
    Tan, Ping
    Tu, Xiang
    Qiu, Yang
    Song, Turun
    Lin, Tao
    TRANSPLANT INTERNATIONAL, 2017, 30 : 352 - 352
  • [34] Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antiviral Agents in Kidney Transplant Recipients with HCV: A Systematic Review and Meta-Analysis.
    Wang, X.
    Tan, P.
    Xiang, T.
    Qiu, Y.
    Song, T.
    Lin, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 941 - 941
  • [35] C-SALVAGE: GRAZOPREVIR (GZR; MK-5172), ELBASVIR (EBR; MK-8742) AND RIBAVIRIN (RBV) FOR CHRONIC HCV-GENOTYPE 1 (GT1) INFECTION AFTER FAILURE OF DIRECT-ACTING ANTIVIRAL (DAA) THERAPY
    Forns, X.
    Gordon, S.
    Zuckerman, E.
    Lawitz, E.
    Buti, M.
    Calleja Panero, J.
    Hofer, H.
    Gilbert, C.
    Palcza, J.
    Howe, A.
    DiNubile, M.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Sullivan-Bolyai, J.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S190 - S190
  • [36] RETREATMENT AND RESISTANCE-ASSOCIATED SUBSTITUTIONS IN HEPATITIS C PATIENTS WHO FAILED DIRECT-ACTING ANTIVIRAL THERAPY IN KOREA
    Kim, Kyung-Ah
    Jeong, Sook-Hyang
    Kim, Seungtaek
    Park, Hye Jung
    Lee, Sejoon
    Jang, Eun Sun
    Lee, Youn-Jae
    Cho, Sung Bum
    Kim, Young Seok
    Lee, Byung Seok
    Chung, Woo Jin
    HEPATOLOGY, 2022, 76 : S361 - S362
  • [37] Differential effects of HCV therapy with direct-acting antiviral agents on lipids in the German multicenter cohort on direct antiviral agents in HCV-and HIV/HCV-infected patients (GECCO)
    Mauss, S.
    Berger, F.
    Ingiliz, P.
    Hueppe, D.
    Lutz, T.
    Simon, K. G.
    Schewe, K.
    Wasmuth, J. C.
    Busch, H.
    Baumgarten, A.
    Christensen, S.
    ANTIVIRAL THERAPY, 2015, 20 : A4 - A5
  • [38] The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
    Nagaoki, Yuko
    Imamura, Michio
    Aikata, Hiroshi
    Daijo, Kana
    Teraoka, Yuji
    Honda, Fumi
    Nakamura, Yuki
    Hatooka, Masahiro
    Morio, Reona
    Morio, Kei
    Kan, Hiromi
    Fujino, Hatsue
    Kobayashi, Tomoki
    Masaki, Keiichi
    Ono, Atsushi
    Nakahara, Takashi
    Kawaoka, Tomokazu
    Tsuge, Masataka
    Hiramatsu, Akira
    Kawakami, Yoshiiku
    Hayes, C. Nelson
    Miki, Daiki
    Ochi, Hidenori
    Chayama, Kazuaki
    PLOS ONE, 2017, 12 (08):
  • [39] Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure
    Tojima, Hiroki
    Kakizaki, Satoru
    Takakusagi, Satoshi
    Hoshino, Takashi
    Naganuma, Atsushi
    Nagashima, Tamon
    Namikawa, Masashi
    Ueno, Takashi
    Shimada, Yasushi
    Hatanaka, Takeshi
    Takizawa, Daichi
    Arai, Hirotaka
    Sato, Ken
    Takagi, Hitoshi
    Uraoka, Toshio
    HEPATOLOGY RESEARCH, 2020, 50 (03) : 303 - 312
  • [40] Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2
    Ohya, Kazuki
    Akuta, Norio
    Suzuki, Fumitaka
    Fujiyama, Shunichiro
    Kawamura, Yusuke
    Kominami, Yoko
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Suzuki, Yoshiyuki
    Saitoh, Satoshi
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (05) : 919 - 925
12345